Logotipo del repositorio
Logotipo del repositorio
 

Cuidados paliativos en la enfermedad de Huntington: perspectivas desde la atención de enfermería

Vista sencilla de ítem
datacite.rightshttp://purl.org/coar/access_right/c_16ecspa
dc.contributor.authorNavarro, Ana
dc.contributor.authorGonzález, Mileidys
dc.contributor.authorJiménez, Jennifer
dc.contributor.authorMartínez, Gabriela
dc.contributor.authorMejía, Cesar
dc.contributor.authorMendoza, Yulianis
dc.contributor.authorPolo, Francesca
dc.contributor.authorTorre, Geraldine
dc.contributor.authorTurizo, Natali
dc.contributor.authorMostapha, Ahmad
dc.date.accessioned2022-02-24T21:24:38Z
dc.date.available2022-02-24T21:24:38Z
dc.date.issued2021
dc.description.abstractIntroducción: La enfermedad de Huntington (EH) es un trastorno neurodegenerativo autosómica dominante, caracterizada por alteraciones motoras, cognitiva y neuro-psiquiátrica, por consiguiente se busca describir los cuidados paliativos de la enfermedad de Huntington desde la perspectiva de enfermería, con el propósito de aportar conocimiento sobre el tratamiento y contribuir a la orientación que puedan ayudar a mejorar la calidad de vida de los pacientes y de sus cuidadores. Conclusiones y recomendaciones: la EH se puede abordar desde diferentes dominios como: dominio funcional, emocional, motor, nutricional y de comportamiento, teniendo en cuenta las necesidades que se presenta en cada dominio se establece las actividades terapéuticas, desde los cuidados paliativos con perspectiva de enfermería, orientado sobre la atención integral activa y continua del paciente-familia donde su finalidad no será como tal la cura de la enfermedad, sino que buscan brindar una mejor calidad de vida para los pacientes y sus familiares.spa
dc.description.abstractIntroduction: Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder, characterized by motor, cognitive and neuro-psychiatric alterations, at last it seeks to describe the palliative care of Huntington's disease from the nursing perspective, with the purpose of provide knowledge about treatment and contribute to guidance that can help improve the quality of life of patients and their caregivers. Conclusions and recommendations: HE can be approached from different domains such as: functional, emotional, motor, nutritional and behavioral domain, taking into account the needs that are presented in each domain, therapeutic activities are established, from palliative care with a perspective of nursing, oriented on the active and continuous comprehensive care of the patient-family where its purpose will not be as the cure of the disease, but rather they seek to provide a better quality of life for patients and their families.eng
dc.format.mimetypepdfspa
dc.identifier.urihttps://hdl.handle.net/20.500.12442/9395
dc.language.isospaspa
dc.publisherEdiciones Universidad Simón Bolívarspa
dc.publisherFacultad de Ciencias de la Saludspa
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.accessrightsinfo:eu-repo/semantics/restrictedAccessspa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectCuidado paliativospa
dc.subjectCuidado de enfermeríaspa
dc.subjectEnfermedad Huntingtonspa
dc.subjectDominios alteradosspa
dc.subjectPalliative careeng
dc.subjectNursing careeng
dc.subjectHuntington's diseaseeng
dc.subjectAltered domainseng
dc.titleCuidados paliativos en la enfermedad de Huntington: perspectivas desde la atención de enfermeríaspa
dc.type.driverinfo:eu-repo/semantics/bachelorThesisspa
dc.type.spaTrabajo de grado - pregradospa
dcterms.referencesL. Bayliss, V. Galvez, A. Ochoa-morales, M. Chávez-oliveros, G. Delgado-garcía, and M. C. Boll, “Theory of mind impairment in Huntington’s disease patients and their relatives,” no. May, pp. 574–578, 2019.eng
dcterms.referencesE. Pyo, M. E. Macdonald, V. C. Wheeler, and L. Jones, “Huntington’s Disease Pathogenesis : Two Sequential Components,” vol. 10, pp. 35–51, 2021, doi: 10.3233/JHD-200427.eng
dcterms.referencesJ. Michel, R. Pupo, Y. Viviana, D. Rojas, and Y. Rojas, “Actualización en enfermedad de Huntington Update on Huntington Disease,” pp. 546–557.spa
dcterms.referencesC. Ohlmeier, K. Saum, W. Galetzka, D. Beier, and H. Gothe, “Epidemiology and health care utilization of patients suffering from Huntington ’ s disease in Germany : real world evidence based on German claims data,” pp. 1–8, 2019.eng
dcterms.referencesALFONSO and HS, “Caracterizacion de las secuencias polimorficas de tripletes CAG y CCG del gen de la enfermedad de Huntington en familias colombianas,” Acta Med Colomb, vol. 12, pp. 70–75, 1996, Accessed: Sep. 05, 2021. [Online]. Available: http://ci.nii.ac.jp/naid/10021247795/en/.spa
dcterms.referencesC. D. E. Revisi and R. Article, “Cuidados paliativos en la enfermedad de Huntington : perspectivas desde la atención primaria de salud .,” vol. 79, no. 4, 2016.spa
dcterms.referencesN. F. Borda, S. Nurczyk, and V. Diaz-videla, “NURSING MODELS PALLIATIVE CARE AND THEORIES : SUPPORT FOR MODELOS Y TEORÍAS DE ENFERMERÍA : SUSTENTO PARA LOS CUIDADOS PALIATIVOS MODELOS E TEORIAS DE ENFERMAGEM : SUPORTE PARA CUIDADOS PALIATIVOS,” vol. 8, pp. 44–56, 2019.spa
dcterms.referencesC. Rubén et al., “Síndrome de Huntington : revisión bibliográfica y actualización Huntington syndrome : bibliographic review and update Síndrome de Huntington : revisão e atualização bibliográfica,” no. 4, 2020, doi: 10.26820/recimundo/4.(4).octubre.2020.392-398.spa
dcterms.referencesR. Ghosh and S. J. Tabrizi, “Clinical Features of Huntington ’ s Disease,” 2018.eng
dcterms.referencesP. L. Faber et al., “Clinical Neurophysiology Fundamentally altered global- and microstate EEG characteristics in Huntington ’ s disease,” Clin. Neurophysiol., vol. 132, no. 1, pp. 13–22, 2021, doi: 10.1016/j.clinph.2020.10.006.eng
dcterms.referencesT. Hünefeldt, S. Maffi, S. Migliore, F. Squitieri, and M. O. Belardinelli, “Emotion recognition and inhibitory control in manifest and pre-manifest Huntington ’ s disease : evidence from a new Stroop task,” 2019, doi: 10.4103/1673-5374.274342.eng
dcterms.referencesK. Duff, J. S. Paulsen, L. J. Beglinger, D. R. Langbehn, and J. C. Stout, “Psychiatric Symptoms in Huntington’s Disease before Diagnosis: The Predict-HD Study,” Biol. Psychiatry, vol. 62, no. 12, pp. 1341–1346, 2007, doi: 10.1016/j.biopsych.2006.11.034.eng
dcterms.referencesM. Imbert, F. Blandel, C. Leumann, L. Garcia, and A. Goyenvalle, “Lowering Mutant Huntingtin Using Tricyclo-DNA Antisense Oligonucleotides As a Therapeutic Approach for Huntington’s Disease,” Nucleic Acid Ther., vol. 29, no. 5, pp. 256–265, 2019, doi: 10.1089/nat.2018.0775.eng
dcterms.referencesL. L. Sokol et al., “Meaning and purpose in Huntington’s disease: a longitudinal study of its impact on quality of life,” Ann. Clin. Transl. Neurol., vol. 8, no. 8, pp. 1668–1679, 2021, doi: 10.1002/acn3.51424.eng
dcterms.referencesN. E. Carlozzi et al., “Patient-Reported Outcomes in Huntington ’ s Disease : Quality of Life in Neurological Disorders ( Neuro-QoL ) and Huntington ’ s Disease Health-Related Quality of Life ( HDQLIFE ) Physical Function Measures,” vol. 00, no. 00, pp. 1–6, 2017, doi: 10.1002/mds.27046.eng
dcterms.referencesC. Fusilli et al., “Biological and clinical manifestations of juvenile Huntington’s disease: a retrospective analysis,” Lancet Neurol., vol. 17, no. 11, pp. 986–993, 2018, doi: 10.1016/S1474-4422(18)30294-1.eng
dcterms.referencesF. Paz-Rodríguez et al., “Neuropsychological performance and disease burden in individuals at risk of developing Huntington disease,” Neurologia, no. xxxx, 2021, doi: 10.1016/j.nrl.2021.04.015.eng
dcterms.referencesU. Desarrollo, C. De Vida, R. C. De Neuropsicología, and U. Desarrollo, “Alteraciones Neurofisiológicas producidas por la Enfermedad de Huntington sobre la Calidad de Vida,” 2016, doi: 10.5839/rcnp.2016.11.02.08.spa
dcterms.referencesG. Neri-Nani et al., “Consenso Mexicano sobre el diagnóstico de la enfermedad de Huntington,” Arch. Neurociencias, vol. 21, no. 1, pp. 64–72, 2016, doi: 10.31157/archneurosciencesmex.v21i1.112.spa
dcterms.references“CUIDADOS DE ENFERMERÍA EN LA ENFERMEDAD DE HUNTINGTON,” 2017.spa
dcterms.referencesM. Nance et al., “Guía para Medico sobre el Manejo de la enfermedad de Huntington Tercera edición.”spa
dcterms.referencesM.-C. Boll, E. Melissa Báez Martínez, A. Ochoa, M. E. Alonso, M. Velasco, and S. México, “Análisis del deterioro cognoscitivo en pacientes con enfermedad de Huntington mediante las pruebas de la escala unificada (UHDRS),” 2008.spa
dcterms.referencesHuntington Study Group, “Unified Huntington’s Disease Rating Scale: Reliabilityand-Consistency,” 1996. doi: doi: 10.1002/mds.870110204.eng
dcterms.referencesC. Cepeda and X. P. Tong, “Huntington’s disease: From basic science to therapeutics,” CNS Neurosci. Ther., vol. 24, no. 4, pp. 247–249, 2018, doi: 10.1111/cns.12841.eng
dcterms.referencesA. Kumar, V. Kumar, K. Singh, S. Kumar, and Y. Kim, “brain sciences Therapeutic Advances for Huntington ’ s Disease,” Brain Sci., pp. 1–20, 2020.eng
dcterms.referencesand A.-M. Y. Young Hee Choi, “乳鼠心肌提取 HHS Public Access,” Physiol. Behav., vol. 176, no. 3, pp. 139–148, 2019, doi: 10.1007/s00415-017-8677-7.A. [eng
dcterms.referencesM. Ciosi et al., “Library preparation and MiSeq sequencing for the genotyping-by-sequencing of the Huntington disease HTT exon one trinucleotide repeat and the quantification of somatic mosaicism,” 2020, doi: 10.21203/rs.2.1581/v2.eng
dcterms.referencesM. Alejandra Rosales-Reynoso Patricio Barros-Núñez and F. Salamanca-Gómez, “Diagnóstico molecular de la enfermedad de Huntington BIOLOGÍA MOLECULAR Y MEDICINA,” 2008. [Online]. Available: www.anmm.org.mx.spa
dcterms.referencesA. Kim et al., “New avenues for the treatment of huntington’s disease,” International Journal of Molecular Sciences, vol. 22, no. 16. MDPI AG, Aug. 02, 2021, doi: 10.3390/ijms22168363.eng
dcterms.referencesB. Zeitler et al., “Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington’s disease,” Nat. Med., vol. 25, no. 7, pp. 1131–1142, 2019, doi: 10.1038/s41591-019-0478-3.eng
dcterms.referencesT. A. Mestre et al., “Rating Scales for Behavioral Symptoms in Huntington ’ s Disease : Critique and Recommendations Organization and Critique Process Identified Scales and Their Utilization in,” vol. 00, no. 00, pp. 1–13, 2016, doi: 10.1002/mds.26675.eng
dcterms.referencesJ. W. Shin et al., “Permanent inactivation of Huntington’s disease mutation by personalized allele-specific CRISPR/Cas9,” Hum. Mol. Genet., vol. 25, no. 20, pp. 4566–4576, 2016, doi: 10.1093/hmg/ddw286.eng
dcterms.referencesL. Gitleman, “済無No Title No Title No Title,” Pap. Knowl. . Towar. a Media Hist. Doc., 2014.eng
dcterms.referencesM. Jimenez-Sanchez, F. Licitra, B. R. Underwood, and D. C. Rubinsztein, “Huntington’s disease: Mechanisms of pathogenesis and therapeutic strategies,” Cold Spring Harb. Perspect. Med., vol. 7, no. 7, pp. 1–22, 2017, doi: 10.1101/cshperspect.a024240.eng
dcterms.referencesG. E. B. Wright et al., “Interrupting sequence variants and age of onset in Huntington’s disease: clinical implications and emerging therapies,” Lancet Neurol., vol. 19, no. 11, pp. 930–939, 2020, doi: 10.1016/S1474-4422(20)30343-4.eng
dcterms.referencesJ. Robinson, M. Gott, C. Gardiner, and C. Ingleton, “Specialist palliative care nursing and the philosophy of palliative care: A critical discussion,” Int. J. Palliat. Nurs., vol. 23, no. 7, pp. 352–358, 2017, doi: 10.12968/ijpn.2017.23.7.352.eng
dcterms.referencesM. R. Ekkel, M. F. I. A. Depla, E. M. L. Verschuur, R. B. Veenhuizen, C. M. P. M. Hertogh, and B. D. Onwuteaka-philipsen, “Gaining insight into the views of outpatients with Huntington ’ s disease regarding their future and the way they deal with their poor prognosis : a qualitative study,” pp. 1–8, 2021.eng
dcterms.references“https://repository.udca.edu.co/handle/11158/933,” p. 190390, 2021, doi: 10.3233/JHD-190390.spa
dcterms.referencesC. G. Tarolli, A. M. Chesire, K. M. Biglan, E. Phase, C. Development, and E. Lilly, “Reviews Palliative Care in Huntington Disease : Personal Reflections and a Review of the Literature,” pp. 1–8, 2017, doi: 10.7916/D88057C7.eng
dcterms.referencesS. Patricia, M. Castrillón, and A. Analidis, “Artículo Original Índice modificado de esfuerzo en cuidadores informales de personas con Enfermedad de Huntington en los Municipios de Algarrobo , Ariguaní y San Angel . Magdalena , Colombia,” vol. 23, no. 1, pp. 3–7, 2017.spa
dcterms.referencesJ. Suárez Rojas and M. Vásquez Cerdas, “Beneficios de la terapia física en la enfermedad de Huntington,” Rev. Neuroeje, vol. 28(1), pp. 24-36, vol. 28, no. 1, 2015.spa
dcterms.referencesD. Dash and T. A. Mestre, “Therapeutic Update on Huntington’s Disease: Symptomatic Treatments and Emerging Disease-Modifying Therapies,” Neurotherapeutics, vol. 17, no. 4, pp. 1645–1659, 2020, doi: 10.1007/s13311-020-00891-w.eng
dcterms.referencesC. B. Moskowitz and A. K. Rao, “Making a measurable difference in advanced Huntington disease care,” in Handbook of Clinical Neurology, vol. 144, 2017.eng
dcterms.referencesK. E. Anderson et al., “Un co cte d Au tho r P Clinical Management of Neuropsychiatric roo f cte d Au tho r P roo f Un co,” pp. 1–10, doi: 10.3233/JHD-180293.eng
dcterms.referencesN. E. Karagas, N. Pessoa, and E. Furr, “Irritability in Huntington ’ s Disease,” vol. 9, pp. 107–113, 2020, doi: 10.3233/JHD-200397.eng
dcterms.referencesJ. Charles et al., “Presentation and care of a family with Huntington disease in a resource-limited community,” J. Clin. Mov. Disord., vol. 4, no. 1, 2017, doi: 10.1186/s40734-017-0050-6.eng
dcterms.referencesV. E. Bianchi, P. F. Herrera, and R. Laura, “Effect of nutrition on neurodegenerative diseases. A systematic review,” Nutr. Neurosci., vol. 24, no. 10, pp. 810–834, 2021, doi: 10.1080/1028415X.2019.1681088.eng
dcterms.referencesR. Cubana de Alimentación Nutrición, T. Rodríguez Graña, L. Velázquez Pérez, and S. Santana Porbén, “Revisión temática,” RCAN Rev Cuba. Aliment Nutr, vol. 1, no. 1, p. 2221, 2019.spa
dcterms.referencesO. R. Breve et al., “Una mirada con lupa a las vulnerabilidades de las personas con enfermedad de Huntington,” no. 28, pp. 1–3, 2018, doi: 10.1001/jama.2013.281053.8.spa
dcterms.referencesN. E. Fritz et al., “Relationships among apathy, health-related quality of life, and function in huntington’s disease,” J. Neuropsychiatry Clin. Neurosci., vol. 30, no. 3, pp. 194–201, 2018, doi: 10.1176/appi.neuropsych.17080173.eng
dcterms.referencesA. L. Teixeira, L. C. De Souza, N. P. Rocha, E. Furr-Stimming, and E. C. Lauterbach, “Revisitando a neuropsiquiatria da doença de huntington,” Dement. e Neuropsychol., vol. 10, no. 4, pp. 261–266, 2016, doi: 10.1590/s1980-5764-2016dn1004002.eng
dcterms.referencesM. Ciosi et al., “Approaches to Sequence the HTT CAG Repeat Expansion and Quantify Repeat Length Variation,” J. Huntingtons. Dis., vol. 10, no. 1, pp. 53–74, 2021, doi: 10.3233/JHD-200433.eng
dcterms.referencesM. van Bruggen-Rufi, A. Vink, W. Achterberg, and R. Roos, “Music therapy in Huntington’s disease: A protocol for a multi-center randomized controlled trial,” BMC Psychol., vol. 4, no. 1, pp. 1–9, 2016, doi: 10.1186/s40359-016-0146-z.eng
dcterms.referencesN. E. Carlozzi et al., “A new measure for end of life planning, preparation, and preferences in Huntington disease: HDQLIFE end of life planning,” J. Neurol., vol. 265, no. 1, 2018, doi: 10.1007/s00415-017-8677-7.eng
dcterms.referencesL. Quinn, D. Kegelmeyer, A. Kloos, A. K. Rao, M. Busse, and N. E. Fritz, “Clinical recommendations to guide physical therapy practice for Huntington disease,” Neurology, vol. 94, no. 5, pp. 217–228, 2020, doi: 10.1212/WNL.0000000000008887.eng
dcterms.referencesM. Milena, P. Melgarejo, A. Mar, T. Herrera, J. Melisa, and O. Ospino, “Calidad de Vida en pacientes diagnosticados con enfermedad de Huntington y sus cuidadores en el del Departamento del Magdalena Quality of life in patients with Huntington’s disease and family caregivers of Magdalena Department,” 2017.spa
dcterms.referencesC. Vidal Marín, “Tratamiento Neuropsicológico en la Enfermedad de Huntington: Una revisión sistemática,” Rev. Discapacidad, Clínica y Neurociencias, vol. 4, no. 1, p. 57, 2017, doi: 10.14198/dcn.2017.4.1.05.spa
dcterms.referencesN. S. Caron, G. E. B. Wright, M. R. Hayden, and C. Frcp, “Huntington Disease Summary Suggestive Findings,” pp. 1–34, 2019.eng
dcterms.referencesM. E. Gómez-Gómez and S. C. Zapico, “Frailty, cognitive decline, neurodegenerative diseases and nutrition interventions,” Int. J. Mol. Sci., vol. 20, no. 11, 2019, doi: 10.3390/ijms20112842.eng
dcterms.referencesA. Peinemann, S. Schuller, C. Pohl, T. Jahn, A. Weindl, and J. Kassubek, “Executive dysfunction in early stages of Huntington’s disease is associated with striatal and insular atrophy: A neuropsychological and voxel-based morphometric study,” J. Neurol. Sci., vol. 239, no. 1, pp. 11–19, 2005, doi: 10.1016/j.jns.2005.07.007.eng
oaire.versioninfo:eu-repo/semantics/acceptedVersionspa
sb.programaEnfermeríaspa
sb.sedeSede Barranquillaspa

Archivos

Colecciones

Pregrado
Artículos

Universidad Simón Bolívar: Todos los derechos reservados / Sistema de biblioteca